Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LHFPL tetraspan subfamily member 6 protein (LHFPL6)
- Target
- LHFPL6
- Molecular classification
- Tetraspan transmembrane protein, Other (specifically, the LHFP family within tetraspan superfamily)
01
Overview
LHFPL tetraspan subfamily member 6 protein (LHFPL6) is a member of the lipoma HMGIC fusion partner gene family and classified within the superfamily of tetraspan transmembrane proteins[1][3][4]. It was first identified in association with benign lipomas as a fusion partner of the HMGA2 gene, implicating it in chromosomal translocation-associated tumorigenesis[1][2][3]. Recent research demonstrates LHFPL6 is upregulated in gastric cancer, correlating with increased pathological stage, poor prognosis, and activation of epithelial–mesenchymal transition (EMT) processes[2]. LHFPL6 is mainly expressed in fibroblasts within the tumor microenvironment and is associated with increased infiltration of immunosuppressive M2 macrophages, contributing to cancer cell migration, invasion, and metastasis[2]. LHFPL6, therefore, functions as a prognostic biomarker and is considered a therapeutic target in gastric cancer and possibly other soft tissue neoplasms[1][2][3].
- Other names
- LHFPL6LHFPLipoma HMGIC fusion partnerMGC22429LHFPL tetraspan subfamily member 6 protein
02
Biological functions
Epithelial–mesenchymal transition (EMT)Regulation of actin cytoskeletonExtracellular matrix organizationSignal transduction (by analogy to other tetraspan proteins)Cell–cell adhesionPossible involvement in immune modulation
03
Disease associations
Cancer (especially gastric cancer, soft tissue chondroma, and familial multiple lipomatosis)Lipoma/Benign adipose tumor
04
Biomarkers
Overexpression of LHFPL6 is associated with poor prognosis and progression in gastric cancerLHFPL6 as a potential prognostic biomarker for epithelial-mesenchymal transition activation and M2 macrophage abundance in tumors
Beyond the preview
Go deeper on LHFPL tetraspan subfamily member 6 protein (LHFPL6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LHFPL tetraspan subfamily member 6 protein (LHFPL6).